While immunotherapy has emerged as a promising therapeutic approach, the heterogeneous expression of PD1, PD-L1, and CTLA-4 in a large series of ACC cases may explain the varied results of immunotherapies in advanced ACC [5,6]. Here, CTLA4 is linked to adrenal cortex carcinoma.